Oleg Krijanovski MD. PhD, is a community based Hematologist/Oncologist practicing at the Alta Bates Summit Comprehensive Cancer Center, Sutter Health in Berkeley, CA where he is serving as a Director of the Medical Oncology, and is heading Malignant Hematology & Cellular Therapy/HSCT programs.  

After completion of Internal Medicine Residency & Hematology/Oncology/BMT fellowship at the University of Michigan (Ann Arbor, MI) in 2005, Dr. Krijanovski had served as Clinical Assistant Professor at the Division of Hematology/Oncology at the University of Michigan, before joining the practice at ABCCC.

He cross-trained in Hematopathology and Blood Banking/ Apheresis, and had a prior experience of establishing and running a successful BMT program in Moscow, Russia prior to coming to Dana Farber Cancer Institute/Harvard Medical School, Boston MA in 1995 as a post-doctoral research fellow.

Selected Bibliography:

1. Krijanovski OI, Hill GR, Cooke KR, Teshima T, Crawford JM, Brinson YS, Ferrara JL. Keratinocyte Growth Factor Separates Graft-versus-Leukemia Effects from Graft-versus-Host-Disease. Blood 94 (2):825-831, July 15, 1999.
2. Hill GR, Teshima T, Rebel VI, Krijanovski OI, Cooke KR, Brinson YS, Ferrara JLM. The p55 TNF-Alpha Receptor Plays a Critical Role in T Cell Alloreactivity. Journal of Immunology 164(2):656-663, January 15, 2000.
3.  Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JLM. A Crucial Role for Antigen-Presenting Cells and Alloantigen Expression in Graft-versus-Leukemia Responses. Nature Medicine, 11: 1244-9, 2005.
4. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL.  Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.  Blood 111(4):2470-2475, February 15 2008, EPub November 27, 2007.
5. Peres E, Levine J, Kato K, Krijanovski O, Khaled Y, Ferrara J, Yanik G, Mineishi S.  Reduced Intensity Versus Full Myeloablative Stem Cell Transplant for Advanced Chronic Lymphocytic Leukemia.  Biology of Blood and Marrow Transplantation 14(2): 62, February 2008.
6. Kato K, Krijanovski O, Khaled Y, Peres E, Reddy P, Choi S, Kitko C, Yanik G, Levine J, Ferrara J, Mineishi S.  Allogeneic Hematopoietic Stem Cell Transplantation has Curative Potential for Chemorefractory Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation 14(2): 63-64, February 2008.
7. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E, Maeda Y, Tawara I, Krijanovski O, Gatza E, Liu C, Malter C, Mascagni P, Dinarello CA, Ferrara JL. Histone Deacetylase Inhibition Modulates Indoleamine 2,3-Dioxygenase-Dependent DC Functions and Regulates Experimental Graft-Versus-Host Disease in Mice. Journal of Clinical Investigation 118(7): 2562-2573, July 1, 2008.
8. Krijanovski O, Paczesny S, Braun T, Choi S, Clouthier S, Kuick R, Misek D, Cooke K, Kitko C, Weyand A, Bickley D, Jones D, Whitfield J, Reddy P, Levine J, Hanash S, Ferrara JLM. A Biomarker Panel for Acute Graft Versus Host Disease. Blood, 2009.
9. Peres E, Braun T, Krijanovski O, Khaled Y, Levine JE, Yanik G, Kato K, Mineishi S. Reduced intensity versus full myeloablative stem cell transplant for advanced CLL. Bone Marrow Transplant. 2009 Mar 23.
10. Peres E, Levine JE, Khaled YA, Ibrahim RB, Braun TM, Krijanovski OI, Mineishi S, Abidi MH. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation Bone Marrow Transplant. 2009 May 25.
11. Khaled Y, Reddy P, Krijanovski O.   Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):219-32.
12. Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30.
13. Waller EK, Logan BR, Harris WA, Devine SM, Porter DL, Mineishi S, McCarty JM, Gonzalez.CE, Spitzer TR, Krijanovski OI, Linenberger ML, Woolfrey A, Howard A, Wu J, Confer DL, Anasetti C. Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or Naïve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201.  J Clin Oncol. 2014 Aug 1;32(22):2365-72. doi: 10.1200/JCO.2013.54.4577. Epub 2014 Jun 30.